Firefighter Paul Whitaker, aged 42, received a devastating diagnosis following episodes of dizziness and light-headedness. Initially, doctors suspected a heart issue when he first complained of weakness in 2023.
By April 2024, Paul was diagnosed with a grade three astrocytoma, a fast-growing and recurring form of brain cancer. He underwent an awake craniotomy, seven weeks of radiotherapy, and a year-long course of chemotherapy in tablet form.
Currently, the Watch Commander is raising funds for innovative medical treatment that could potentially extend his time with his family. Additionally, he is advocating for increased awareness about brain tumors, as his symptoms did not align with the typical indicators associated with his condition.
Reflecting on his diagnosis, Paul expressed, “The moment I was told ‘you have a brain tumor,’ our world shattered. The outlook is grim, with an average life expectancy of only a few years. We understand this disease will eventually take my life, but if we can prolong it, we want that chance. While it comes at a cost, what value can you place on life?”
Having served as a firefighter for 17 years, Paul initially experienced dizziness in 2023, seeking medical attention in June of that year. Doctors initially suspected a heart problem, leading to multiple hospital visits for evaluations.
Paul, a devoted husband and father of two, faced a life-altering moment when his wife Hayley, 40, noticed a droop in the left side of his face in April 2024. Following advice from NHS 111 to rush to A&E for a suspected transient ischaemic attack (TIA) or ‘mini stroke,’ an MRI scan revealed a substantial brain lesion.
He was quickly transferred to Addenbrookes Hospital in Cambridge, where he underwent surgery to remove the tumor while awake. Recalling the experience, Paul shared, “Initially, we were unaware of the severity. However, after the tumor was removed and tested, we learned it was a grade three astrocytoma.”
The 42mm tumor necessitated seven weeks of radiotherapy and a year-long regimen of chemotherapy tablets. Paul and Hayley made efforts to shield their children, Noah, eight, and Ethan, six, from the distressing news.
In September, Paul completed his treatment and received positive news of tumor reduction. Nevertheless, due to its aggressive nature, a recurrence is anticipated, prompting Paul to raise funds for an immunotherapy vaccine.
The ADCV treatment, produced similarly to the successful DCVax-L trial at King’s College Hospital, is a personalized vaccine that assists the immune system in identifying and attacking tumor cells. In a notable clinical trial, it more than doubled the five-year survival rate for patients with Grade 4 Glioblastoma.
With a prognosis of three to six years, Paul remains optimistic that this treatment could significantly extend his life span. “As the study focused on grade four tumors and mine is grade three, we are hopeful for an even more positive outlook. The aim is to halt its growth,” Paul stated.
He added, “My son Ethan is passionate about karate and is working towards his black belt. Noah loves football. They do not deserve this, nor does anyone.”
Within a mere ten days, Paul has raised £33,000 toward his £140,000 goal but requires £80,000 for the initial three doses of treatment. Each additional dose costs £23,000, and manufacturing the vaccine amounts to £120,000.
Acknowledging his lack of prior knowledge about brain tumors, Paul emphasized the need for enhanced diagnostic tools for GPs to detect such conditions earlier. He believes that earlier detection might have led to a lower-grade diagnosis.
For those interested in supporting Paul’s cause, his fundraiser is accessible on GoFundMe.